Heidelberg Pharma AG (HPHA.DE)
EUR 2.82
(4.44%)
EUR 2.82
(4.44%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 10.48 Million EUR | 128.74% |
| 2022 | 4.58 Million EUR | 514.68% |
| 2021 | 745.92 Thousand EUR | 224.57% |
| 2020 | 229.82 Thousand EUR | -3.32% |
| 2019 | 237.7 Thousand EUR | 33.87% |
| 2018 | 177.55 Thousand EUR | -0.27% |
| 2017 | 178.03 Thousand EUR | -6.42% |
| 2016 | 190.23 Thousand EUR | -31.86% |
| 2015 | 279.16 Thousand EUR | 47.16% |
| 2014 | 189.71 Thousand EUR | 143.74% |
| 2013 | 77.83 Thousand EUR | -69.86% |
| 2012 | 258.21 Thousand EUR | -49.83% |
| 2011 | 514.62 Thousand EUR | 210.77% |
| 2010 | 165.59 Thousand EUR | 385.63% |
| 2009 | 34.1 Thousand EUR | 53.6% |
| 2008 | 22.2 Thousand EUR | 0.0% |
| 2007 | 22.2 Thousand EUR | 0.0% |
| 2006 | 22.2 Thousand EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 11.49 Million EUR | 9.62% |
| 2024 Q2 | 11.72 Million EUR | 2.0% |
| 2024 Q3 | 12.21 Million EUR | 4.19% |
| 2023 Q3 | 8.89 Million EUR | 70.57% |
| 2023 Q2 | 5.21 Million EUR | -0.84% |
| 2023 Q1 | 5.25 Million EUR | 14.69% |
| 2023 FY | 10.48 Million EUR | 128.74% |
| 2023 Q4 | 10.48 Million EUR | 17.92% |
| 2022 Q4 | 4.58 Million EUR | 8.36% |
| 2022 Q3 | 4.23 Million EUR | 299.87% |
| 2022 FY | 4.58 Million EUR | 514.68% |
| 2022 Q1 | 1.27 Million EUR | 71.19% |
| 2022 Q2 | 1.05 Million EUR | -17.13% |
| 2021 Q1 | 574.85 Thousand EUR | 150.13% |
| 2021 Q4 | 745.92 Thousand EUR | -7.61% |
| 2021 Q2 | 598.05 Thousand EUR | 4.04% |
| 2021 FY | 745.92 Thousand EUR | 224.57% |
| 2021 Q3 | 807.32 Thousand EUR | 34.99% |
| 2020 Q4 | 229.82 Thousand EUR | -25.66% |
| 2020 Q1 | 843.22 Thousand EUR | 254.74% |
| 2020 FY | 229.82 Thousand EUR | -3.32% |
| 2020 Q2 | 583.29 Thousand EUR | -30.83% |
| 2020 Q3 | 309.15 Thousand EUR | -47.0% |
| 2019 Q2 | 40.05 Thousand EUR | -17.62% |
| 2019 FY | 237.7 Thousand EUR | 33.87% |
| 2019 Q1 | 48.62 Thousand EUR | -72.62% |
| 2019 Q3 | 32.19 Thousand EUR | -19.64% |
| 2019 Q4 | 237.7 Thousand EUR | 638.43% |
| 2018 FY | 177.55 Thousand EUR | -0.27% |
| 2018 Q4 | 177.55 Thousand EUR | 292.46% |
| 2018 Q2 | 140.82 Thousand EUR | 72.92% |
| 2018 Q3 | 45.24 Thousand EUR | -67.87% |
| 2018 Q1 | 81.43 Thousand EUR | -54.26% |
| 2017 FY | 178.03 Thousand EUR | -6.42% |
| 2017 Q4 | 178.03 Thousand EUR | 0.34% |
| 2017 Q3 | 177.43 Thousand EUR | 23.71% |
| 2017 Q2 | 143.42 Thousand EUR | -42.14% |
| 2017 Q1 | 247.89 Thousand EUR | 30.31% |
| 2016 Q1 | 311.41 Thousand EUR | 11.55% |
| 2016 FY | 190.23 Thousand EUR | -31.86% |
| 2016 Q4 | 190.23 Thousand EUR | -25.55% |
| 2016 Q3 | 255.5 Thousand EUR | -5.63% |
| 2016 Q2 | 270.76 Thousand EUR | -13.05% |
| 2015 FY | 279.16 Thousand EUR | 47.16% |
| 2015 Q1 | 134.36 Thousand EUR | -29.17% |
| 2015 Q2 | 200.76 Thousand EUR | 49.41% |
| 2015 Q3 | 240.85 Thousand EUR | 19.97% |
| 2015 Q4 | 279.16 Thousand EUR | 15.91% |
| 2014 Q1 | 50.01 Thousand EUR | -35.74% |
| 2014 Q3 | 28.46 Thousand EUR | -44.86% |
| 2014 Q2 | 51.63 Thousand EUR | 3.24% |
| 2014 FY | 189.71 Thousand EUR | 143.74% |
| 2014 Q4 | 189.71 Thousand EUR | 566.37% |
| 2013 Q3 | 127.99 Thousand EUR | -45.08% |
| 2013 Q2 | 233.05 Thousand EUR | 6.8% |
| 2013 Q1 | 218.2 Thousand EUR | -15.49% |
| 2013 FY | 77.83 Thousand EUR | -69.86% |
| 2013 Q4 | 77.83 Thousand EUR | -39.19% |
| 2012 Q3 | 292.45 Thousand EUR | -19.37% |
| 2012 FY | 258.21 Thousand EUR | -49.83% |
| 2012 Q1 | 519.1 Thousand EUR | 0.87% |
| 2012 Q2 | 362.7 Thousand EUR | -30.13% |
| 2012 Q4 | 258.21 Thousand EUR | -11.71% |
| 2011 Q3 | 230.84 Thousand EUR | -6.79% |
| 2011 Q1 | 143.62 Thousand EUR | -13.27% |
| 2011 FY | 514.62 Thousand EUR | 210.77% |
| 2011 Q4 | 514.62 Thousand EUR | 122.93% |
| 2011 Q2 | 247.67 Thousand EUR | 72.45% |
| 2010 Q1 | 34.1 Thousand EUR | 0.0% |
| 2010 FY | 165.59 Thousand EUR | 385.63% |
| 2010 Q4 | 165.59 Thousand EUR | 385.63% |
| 2010 Q3 | 34.1 Thousand EUR | 0.0% |
| 2010 Q2 | 34.1 Thousand EUR | 0.0% |
| 2009 FY | 34.1 Thousand EUR | 53.6% |
| 2009 Q4 | 34.1 Thousand EUR | 0.0% |
| 2008 FY | 22.2 Thousand EUR | 0.0% |
| 2007 FY | 22.2 Thousand EUR | 0.0% |
| 2006 FY | 22.2 Thousand EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| BioNTech SE | 357.7 Million EUR | 97.068% |
| CureVac N.V. | 24.82 Million EUR | 57.747% |
| Biotest Aktiengesellschaft | 419.1 Million EUR | 97.498% |
| Biotest Aktiengesellschaft | 419.1 Million EUR | 97.498% |
| BRAIN Biotech AG | 9.72 Million EUR | -7.833% |
| Formycon AG | 467 Thousand EUR | -2145.78% |
| Medigene AG | 1.00 EUR | -1048779100.0% |